Trial Profile
A Randomized Safety-Assessor Blinded Trial Comparing Sugammadex With Neostigmine in Korean Subjects Scheduled for Surgeries Requiring Moderate Neuromuscular Blockade
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Neostigmine
- Indications Neuromuscular blockade
- Focus Registrational; Therapeutic Use
- Acronyms DANCHEONG
- Sponsors Merck Sharp & Dohme
- 26 Sep 2014 New trial record